Novo, a Danish pharmaceutical company, saw its shares fall up to 7% after announcing plans to launch over five new drugs with blockbuster potential by 2030 and targeting pipeline sales exceeding $23 billion by 2035. The company aims to grow revenue from 2026 to 2030 in line with industry peers, signaling its intent to remain competitive in the crowded obesity drug market it helped pioneer. Despite the ambitious goals, investor confidence was shaken, reflected in the share price drop. Novo's strategy highlights the intense competition and high stakes in the obesity treatment sector moving forward.
Novo Nordisk's shares are trading at USD 40.32 on Pluang, down 6.75% as of Sep 21, 2026 15:11 WIB. The stock's market cap stands at $190.93 billion, with a dividend yield of 4.15%. This data highlights the current market valuation and investor sentiment following the company's recent announcements.
